ProfileJobs

Curis

Healthbiotechdrug developmenthealthtechoncology

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. 

Revenue(Q1, 2017)
$2.1 M
Market capitalization(2017-10-19)
$225.7 M
Company Growth (employees)
Type
Public
HQ
Lexington, US
Founded
2000
Size (employees)
58 (est)+32%
Website
curis.com
Curis was founded in 2000 and is headquartered in Lexington, US

Curis Office Locations

Curis has an office in Lexington
Lexington, US (HQ)
4 Maguire Rd

Curis Financials and Metrics

Curis Financials

Curis's revenue was reported to be $2.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

2.1 m

Net income (Q1, 2017)

(15.7 m)

EBIT (Q1, 2017)

(15.1 m)

Market capitalization (19-Oct-2017)

225.7 m

Cash (31-Mar-2017)

42.4 m
Curis's current market capitalization is $225.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

15 m9.8 m7.9 m7.5 m

Revenue growth, %

(34%)(20%)(4%)

EBIT

(9.4 m)(15.9 m)(56.5 m)(58 m)

EBIT margin, %

(63%)(161%)(717%)(771%)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.8 m1.8 m1.7 m2.1 m2 m1.7 m1.7 m1.8 m2.1 m

R&D expense

3.3 m3.7 m4.7 m5.9 m4 m6.8 m8.8 m6.8 m13.5 m

General and administrative expense

2.9 m2.7 m3.5 m3.4 m2.8 m3.6 m3.4 m4.7 m3.5 m

Operating expense total

6.3 m6.4 m8.2 m9.3 m6.8 m10.4 m12.3 m11.5 m17.1 m
show all
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.6 m7.7 m33.1 m26 m

Accounts Receivable

1.5 m2 m2.1 m2.5 m

Inventories

495.3 k489.8 k1.2 m1.3 m

Current Assets

60.2 m52.2 m85.5 m48.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

10.2 m7.9 m23.5 m31.5 m28.7 m14.7 m8.6 m20.7 m42.4 m

Accounts Receivable

4.8 m1.8 m1.8 m2.1 m2.3 m1.7 m1.9 m1.9 m2.2 m

Current Assets

61 m57.1 m102.6 m102.1 m96.6 m75.8 m64.5 m56.6 m64.4 m

PP&E

439.4 k407.4 k364 k323.1 k315.5 k383.6 k451 k406 k410 k
show all
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.3 m)(18.7 m)(59 m)(60.4 m)

Depreciation and Amortization

141.5 k155.1 k160.8 k193 k

Accounts Receivable

(569.1 k)(483.8 k)(145 k)(353 k)

Cash From Operating Activities

(9.5 m)(16.8 m)(29.9 m)(35.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.9 m)(5.6 m)(31.8 m)(8.1 m)(5.5 m)(9.4 m)(11.3 m)(28.3 m)(15.7 m)

Accounts Receivable

4.8 m1.8 m1.8 m2.1 m2.3 m1.7 m1.9 m1.9 m2.2 m

Accounts Payable

2.8 m2.4 m2.8 m2.4 m2.6 m4.9 m3.9 m5.1 m5.9 m
show all
USDY, 2017

Revenue/Employee

41.8 k

Financial Leverage

3.4 x
Show all financial metrics

Curis Market Value History

Market Position of Curis

Competitors

ImmunoGen
Health - Public
Heat Biologics
Health - Public
XBiotech
Health - Public
Aeglea Biotherapeutics
Health - Public
Compare competitors

Traffic Overview of Curis

Curis Online and Social Media Presence

Curis Company Life and Culture

You may also be interested in